NEOGAP Therapeutics has been granted a patent in Australia for an innovative method that opens new possibilities in the treatment and diagnosis of multiple sclerosis (MS).
The patent strengthens NEOGAP’s strategic intellectual property portfolio and marks an important step in the company’s efforts to develop groundbreaking treatments for autoimmune diseases such as MS, it states.
The patent covers a tolerogenic treatment method for multiple sclerosis (MS). The method utilizes specially designed molecules to influence the immune system’s response, conditioning it to tolerate the body’s cells instead of mistakenly attacking them. Correcting the immune system’s misguided reactions is crucial in treating MS. The patent is valid until 2038.
By integrating the method with its EpiTCer technology, NEOGAP can forge improved treatment methods and diagnostic processes for MS. This amalgamation of patented method and advanced technology unlocks new possibilities for devising innovative and targeted treatment strategies against the disease.
”The new patent marks a milestone that not only strengthens our IP portfolio but also reflects the great potential of our EpiTCer platform,” says Samuel Svensson, CEO of NEOGAP Therapeutics. ”While our primary focus remains on cancer treatment, this patent also signifies an exciting expansion of our research into other vital areas, including MS, where we see considerable potential for our EpiTCer technology. This development allows us to build further on our previous successes in identifying specific molecular markers for MS diagnosis and take an important step forward in our research and development of innovative treatments for autoimmune diseases.”
Beyond its application in MS treatment, the patent also incorporates methods for diagnosing MS, thus improving the prospects for early detection and treatment of the disease, describes the company.
Photo:
